Linoleate produces remission in canine mycosis fungoides

Iwamoto, Keisuke S.; Bennett, Leslie R.; Norman, Amos; Villalobos, Alice; Hutson, C. A.

doi:10.1016/0304-3835(92)90016-o

Cited by 25 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vail et al treated nine dogs with CETL with pegylated liposomal doxorubicin, but with an overall response rate of 44%, this approach seems to be less effective than masitinib . The study of Iwamoto et al using linoleate to treat dogs with CETL showed clinical improvement and reduction or disappearance of lesions in six of eight dogs; however, there was no definition of CR and PR as well as stable and PD, so this study should be interpreted with caution . Pegylated l ‐asparaginase used in seven dogs with CETL led to a median survival of 9 months but responses were only partial and often short lived…”

Section: Discussionmentioning

confidence: 80%

“…17 The study of Iwamoto et al using linoleate to treat dogs with CETL showed clinical improvement and reduction or disappearance of lesions in six of eight dogs; however, there was no definition of CR and PR as well as stable and PD, so this study should be interpreted with caution. 18 Pegylated L-asparaginase used in seven dogs with CETL led to a median survival of 9 months but responses were only partial and often short lived. 3 All except for one dog responding to masitinib did not receive any prior therapy and all three dogs with PD were pretreated, which might indicate that prior treatment may limit the efficacy of masitinib.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Masitinib monotherapy in canine epitheliotropic lymphoma

Holtermann

Kiupel

Kessler

et al. 2015

Vet Comparative Oncology

View full text Add to dashboard Cite

This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-, seven were negative for that receptor. Five showed strong expression of PDGFR-, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Masitinib monotherapy in canine epitheliotropic lymphoma

Holtermann

Kiupel

Kessler

et al. 2015

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…In addition to responses to chemotherapy, a 42% ORR was reported for 14 dogs with cutaneous lymphoma (five with EL) treated with isotretinoin or etretinate for a median of 11 months . Linoleic acid (in the form of safflower oil) resulted in clinical improvement in six of eight dogs with cutaneous EL for up to two years duration; however, it was not clear whether these were CR or PR. The response rates and response duration for dogs receiving retinoids and/or linoleic acid were unable to be determined in this study; however, it was determined that dogs with multiple cutaneous EL treated with retinoids had a significantly longer MST ( P = 0.001, Figure ) that was independent of whether dogs received chemotherapy.…”

Section: Discussionmentioning

confidence: 93%

Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003–2015)

Chan¹,

Frimberger²,

Moore³

2017

Veterinary Dermatology

View full text Add to dashboard Cite

Canine epitheliotropic lymphoma may be divided into cutaneous and mucocutaneous/mucosal forms. Solitary lesions have a better prognosis. Dogs with multiple lesions appear to benefit from chemotherapy and retinoid treatment, with those attaining complete remission having longer survival times. Multi-agent chemotherapy could be considered in dogs with cutaneous lesions that fail to respond to single-agent chemotherapy.

show abstract

“…The most benign of the treatments is linoleic acid at high concentrations. When treated with 3 ml kg −1 sunflower oil, six of eight dogs with CETL markedly improved for up to 2 years 60 . However, larger studies confirming the efficacy are lacking.…”

Section: Prognosis and Treatmentmentioning

confidence: 98%

Canine cutaneous epitheliotropic T‐cell lymphoma: a review

Fontaine

Bovens

Bettenay³

et al. 2009

Vet Comparative Oncology

159

View full text Add to dashboard Cite

Cutaneous epitheliotropic T-cell lymphoma in the dog is a rare neoplastic condition with unknown aetiology. The dermatitis is characterized by infi ltration of neoplastic T lymphocytes with a specifi c tropism for the epidermis and the adnexal structures. The different clinical and histological forms (mycosis fungoides, pagetoid reticulosis and Sézary syndrome) are reviewed. The disease in the dog resembles the human syndrome, but in 80% of the canine cases, neoplastic cells are CD4− in 90% of the human patients. Prognosis is poor with a survival time from few months to 2 years. Treatments frequently have a low effi cacy. New protocols using lomustine may improve the poor prognosis of the disease.

show abstract

Linoleate produces remission in canine mycosis fungoides

Cited by 25 publications

References 9 publications

Masitinib monotherapy in canine epitheliotropic lymphoma

Masitinib monotherapy in canine epitheliotropic lymphoma

Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003–2015)

Canine cutaneous epitheliotropic T‐cell lymphoma: a review

Contact Info

Product

Resources

About